A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISEâ„¢(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice
A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISEâ„¢(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
Open Label, single arm, 2wk titration, 6 wk stable dosing, 8 wk of total treatment, 1wk dose tapering
Inclusion Criteria:
Exclusion Criteria:
Worcestor, Massachusetts, United States
Tom River, New Jersey, United States